Prof. Paolo Ghia discusses the results of a matching-adjusted indirected comparison of acalabrutinib versus zanubrutinib in relapsed or refractory CLL
Ariez Publishing
Prof. Paolo Ghia discusses the results of a matching-adjusted indirected comparison of acalabrutinib versus zanubrutinib in relapsed or refractory CLL
00:00 / 09:00